Garrett Nichols, GlaxoSmithKline, Project Leader, discusses GSK's new Integrase Inhibitor under development, it's dosing, and cross resistance with Merck's Raltegravir.
Interviewed by Fred Schaich, IFARA, at the 5th IAS Conference in Cape Town, South Africa, July 2009.
Ral is gerat
kassel2711 1 year ago